13710 Struthers Rd. Suite 105B
Colorado Springs, CO 80921
1257 Lake Plaza Dr. Suite 105
Colorado Springs, CO 80906
13710 Struthers Rd. Suite 105B
Colorado Springs, CO 80921
1257 Lake Plaza Dr. Suite 105
Colorado Springs, CO 80906
Quick Answer Tirzepatide is a physician-prescribed dual-action weight loss medication that activates both GLP-1 and GIP hormone receptors — producing stronger average weight loss than single-pathway GLP-1 medications. At Colorado Slim in Colorado Springs, Tirzepatide is prescribed after a full diagnostic evaluation with in-person follow-up at every dose adjustment. SURMOUNT-1 trials show average body weight loss of 15–22% depending on dose. Results vary by individual.
Your doctor mentioned your A1C is creeping up. Or your blood pressure medication isn’t working as well as it used to. Or your cholesterol panel came back with numbers that made your physician frown and say — again — that losing weight would help.
What you didn’t get was a program. You got a referral to “eat better and exercise more,” which you’ve been trying to do for years. The frustration isn’t lack of effort. It’s that the standard advice doesn’t account for what’s actually driving the problem: insulin resistance, hormonal disruption, and a metabolism that’s been fighting against you.
Tirzepatide addresses all three. It’s not a stricter version of what you’ve already tried. It’s a different mechanism entirely.
Tirzepatide is a dual GLP-1 and GIP receptor agonist — meaning it activates two hormone pathways simultaneously rather than one. GLP-1 activation reduces appetite and slows gastric emptying; GIP activation targets insulin sensitivity and fat metabolism. Together, SURMOUNT-1 trials showed average body weight loss of 15–22% depending on dose, compared to 15–17% for Semaglutide. A physician evaluation determines which is appropriate for your profile.
Semaglutide works through one hormone receptor. Tirzepatide works through two — and that distinction produces meaningfully different outcomes for the right patients.
GLP-1 receptor activation. Like Semaglutide, Tirzepatide binds to GLP-1 receptors in the hypothalamus, reducing food noise, slowing gastric emptying, and improving blood sugar regulation. This is the mechanism most patients are familiar with from Semaglutide’s clinical profile.
GIP receptor activation. Tirzepatide also activates glucose-dependent insulinotropic polypeptide (GIP) receptors — a second pathway that improves insulin sensitivity and, in preclinical and early clinical studies, appears to enhance fat metabolism by influencing how adipose tissue stores and releases energy. For patients with significant insulin resistance, this second pathway is where Tirzepatide separates from single-agonist medications. The exact mechanisms are still being studied, but the clinical weight loss outcomes are well-documented.
SURMOUNT-1 results: average body weight reduction of 15% at 5mg, 19.5% at 10mg, and 20.9% at 15mg — compared to 14.9–16.9% for Semaglutide in the STEP-1 trial. That gap widens at higher doses. For a patient starting at 240 lbs, the difference between 15% and 21% is roughly 14 lbs.
Results vary by individual. A physician evaluation determines whether Tirzepatide is appropriate for your history and goals.
Tirzepatide is not the right choice for every patient — and a physician evaluation is how that determination gets made. That said, certain profiles tend to see the strongest outcomes with Tirzepatide specifically.
Eligibility is determined by your physician based on your labs, your history, and your goals. Results vary by individual.
These are illustrative clinical scenarios based on common patient profiles. They do not represent specific individuals.
Both Colorado Springs locations are accepting new patients.
The patient managing multiple conditions at once. A 54-year-old with a BMI of 34, on a statin and a blood pressure medication, whose PCP has mentioned weight loss at every appointment for three years but hasn’t had time to build a real program around it. He’s not unaware of the problem. He just hasn’t had a provider whose entire focus is solving it. Tirzepatide’s dual metabolic action — improving insulin sensitivity while reducing weight — often produces improvements in the labs that are driving his other medications.
he patient who tried Semaglutide and wanted more. A 46-year-old who completed six months on Semaglutide through another clinic, lost 18 lbs, and plateaued. She didn’t fail the medication — she may have hit the ceiling of single-pathway GLP-1 therapy for her metabolic profile. Patients with significant insulin resistance often need GIP receptor activation to break through. A physician evaluation at Colorado Slim determines whether switching to Tirzepatide is the right next step, or whether a dosing adjustment addresses the plateau.
The patient with 60 or more pounds to lose. A 41-year-old who has tried every structured program and loses the same 20 lbs before regaining it. At her starting weight, Tirzepatide’s clinical data shows a meaningfully stronger dose-response than Semaglutide. The issue has never been her commitment. It’s that her hormonal environment has been working against sustained loss at a scale the single-pathway medication couldn’t fully correct.
This is the question Colorado Slim’s physician team gets most often from patients who’ve done their research. The honest answer: neither medication is universally superior. The right choice depends on your metabolic profile, your history with prior GLP-1 therapy, and what your labs show. A physician evaluation settles it — not a comparison chart. That said, the chart is a useful starting point.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Hormone receptors activated | GLP-1 only | GLP-1 + GIP (dual) |
| Avg. weight loss (clinical trials) | 15–17% body weight (STEP-1) | 15–22% body weight depending on dose (SURMOUNT-1) |
| Insulin sensitivity improvement | Moderate | Stronger — GIP pathway |
| Best suited for | Patients seeking well-documented, single-pathway GLP-1 therapy | Patients with insulin resistance, higher starting weight, or prior GLP-1 plateau |
| Side effect profile | Well-established; nausea most common | Similar to Semaglutide; GI effects comparable at equivalent titration |
| Clinical track record | Longer (approved 2021 for weight) | Newer but extensive trial data (SURMOUNT series) |
| Availability | Branded shortage; compounded available | Compounded available through physician prescription |
Results vary by individual. Neither medication is appropriate for all patients. A physician evaluation at Colorado Slim determines which, if either, fits your profile.
Tirzepatide is not a prescription you fill and manage alone. The clinical outcomes that make it worth discussing require a titration protocol that’s actively managed — and that requires an in-person physician, not a patient portal.
Colorado Slim begins Tirzepatide at 2.5mg weekly — the standard low starting dose designed to minimize GI side effects while your body adjusts. Doses increase by 2.5mg every four weeks based on your tolerance and response, with a ceiling typically between 10mg and 15mg depending on your physician's assessment. The goal is the lowest effective dose, not the highest tolerated one.
Follow-up visits include weight and body composition review, side effect assessment, and a dosing decision at each appointment. Lab work is repeated at appropriate intervals — not just for safety, but because tracking metabolic markers (A1C, triglycerides, fasting glucose) is how your physician confirms the medication is producing the outcomes beyond the scale that matter for your long-term health. Colorado Slim's blood glucose monitoring tracks the metabolic markers that matter alongside weight
Most patients notice meaningful appetite reduction within the first two to four weeks. Visible weight loss typically accelerates through months two to five as titration progresses. Patients with significant insulin resistance often report lab improvements — reduced fasting glucose, better cholesterol ratios — that precede or accompany scale progress. Both matter. Colorado Slim tracks both.
Tirzepatide’s side effect profile is similar to Semaglutide’s — which is reassuring for patients familiar with GLP-1 therapy, and worth explaining plainly for those who aren’t.
Serious side effects are rare. Every contraindication on that list is reviewed at your initial Colorado Slim evaluation before any prescription is written. Physician oversight isn’t a formality — it’s why the protocol exists.
Mounjaro is the branded version of Tirzepatide, originally approved for type 2 diabetes management. The active ingredient is the same. Colorado Slim prescribes compounded Tirzepatide — prepared in sterile, FDA-registered compounding pharmacies using pharmaceutical-grade ingredients. It is physician-prescribed and monitored, not sourced from unverified online channels.
Semaglutide activates one hormone receptor (GLP-1). Tirzepatide activates two — GLP-1 and GIP. The GIP pathway adds meaningful insulin sensitivity improvement and enhanced fat metabolism that single-agonist medications don’t produce. Clinical trials show Tirzepatide produces stronger average weight loss (20–22% vs. 15–17%), though individual results vary based on metabolic profile.
Potentially, but this requires physician evaluation and coordination. Tirzepatide improves blood sugar regulation, which can interact with existing diabetes medications — particularly insulin and sulfonylureas. Your Colorado Slim physician reviews your full medication list before prescribing and coordinates with your primary care provider as needed.
Pricing depends on dose, frequency, and what’s included in your program. Colorado Slim discusses costs at your initial consultation — no contracts, no membership fees, no hidden charges. CareCredit financing is accepted. Lab work is often covered by insurance, and the team helps navigate that at your visit.
Most patients notice reduced appetite and some early weight change within the first two to four weeks. More significant, consistent weight loss typically becomes visible through months two to five as titration progresses. Patients with insulin resistance often see metabolic lab improvements in the same window — sometimes before scale progress catches up.
Yes, and this is a common conversation at Colorado Slim. Patients who plateaued on Semaglutide — particularly those with underlying insulin resistance — often see renewed progress on Tirzepatide. The switch involves a physician evaluation to determine appropriate starting dose and a titration protocol that accounts for your prior GLP-1 exposure.
13710 Struthers Rd, Suite 105B
Mon–Thu 9am–5pm
Fri 9am–2pm
Sat by appointment
1257 Lake Plaza Dr, Suite 105
Mon, Wed, Thu
9am–2pm
Colorado Slim’s initial consultation reviews your labs, your metabolic history, and whether Tirzepatide — or Semaglutide, or a combination approach — fits your specific situation. You won’t leave with a prescription you don’t understand or a program built from a template.
No contracts. No membership fees. Both Colorado Springs locations are accepting new patients.
